Claim Validation — The Grand Velocity Machine: An All-in-One Isokinetic Dynamometer

Companion to grand-velocity-machine.md. Legend & severity in _claims/README.md. Bottom line: The modality definitions (isokinetic / isometric / isotonic) and the concept of bilateral + unilateral isokinetic assessment with agonist/antagonist (flexion/extension) balance ratios are textbook-established and cited. Product specs (2–600°/sec, footprint W 1.8 m × L 2.5 m, bench −30° to 90°, 80 data fields, two motors) match the source catalogue verbatim and need client confirmation, not external sourcing. The two items that must be edited before leaving noindex are: (1) AU Patent 2020101146 is an Innovation Patent, not a standard patent — and the blog’s own RESEARCH NEEDED flag is correct; the patent’s current registry status is “Certified” with expiry 25-June-2028, applicant Kickoff, LLC (assigned from Alan Maynard, Feb 2026) — and, crucially, the patent covers a multifunctional computerized isokinetic system, not the “Pressure Resistance System” or oil-temperature-compensation specifically, so the patent cannot be cited as proof of the PRS claim; (2) the “regenerate injured muscle tissue” clinical claim is biologically inaccurate (devices support rehabilitation, they do not biologically regenerate tissue) and must be softened, with clinical sign-off. The Biodex comparison is already framed as “positioned as an alternative” — keep it that way; do not add any superiority claim, because Biodex offers six modes (vs. three on the Grand Velocity) and is the published reference standard in >1,000 studies.

Claims

1. Three modalities: isokinetic, isometric, isotonic (definitions & use) · 🟢 · ✅

  • In post: “The Grand Velocity Machine is an all-in-one isokinetic, isometric and isotonic unit … Run isokinetic tests at a controlled constant speed … Apply isometric protocols to load a joint at a fixed angle without movement … Use isotonic options for more conventional concentric and eccentric conditioning.”
  • Finding: The three modality definitions are textbook-accurate and the distinguishing principle of each is correctly stated. Isokinetic = constant angular velocity with accommodating resistance; isometric = no joint movement / fixed angle; isotonic = constant load with varying velocity.
  • Evidence:
  • Recommendation: KEEP. Optionally CITE one of the above on the post.
  • Notes: The “all-in-one unit offering all three” is a product configuration claim → see Claim 11 (catalogue spec).

2. Two motors enable unilateral AND bilateral testing · 🟠 · 🟡

  • In post: “It is built with two motors, allowing it to measure both unilateral (one limb at a time) and bilateral (both limbs together) function.”
  • Finding: The GENERAL concept is well established — isokinetic dynamometry is used in both unilateral (single-limb) and bilateral (both-limbs-simultaneous) configurations, and bilateral/unilateral strength assessment is a standard clinical methodology. The specific “two-motor” mechanism that enables both modes on one machine is a proprietary engineering claim found in the client’s catalogue; no public independent source confirms the motor count or that two motors are required for bilateral isokinetic measurement. Biodex achieves unilateral + reciprocal limb testing via a single dynamometer head, so “two motors” is a Velocity-specific design choice, not an industry requirement.
  • Evidence:
  • Recommendation: KEEP the concept (unilateral + bilateral isokinetic testing is standard); CONFIRM-CLIENT on the “two motors” engineering detail. Do not present two motors as an industry requirement or as superior to single-dynamometer designs.
  • Notes: The catalogue lists “Unilateral and Bilateral Exercise System” as a feature of the Grand Velocity Machine; the Glute (“Hamstring Runner”) reference page also describes “dual motors used in unilateral or bilateral motions.”

3. Simultaneously measures flexion/extension balance ratios · 🟠 · 🟡

  • In post: “the system is able to simultaneously measure flexion and extension balance ratios — the kind of data that reveals side-to-side asymmetries and muscle imbalances long before they surface as pain or injury.”
  • Finding: The underlying assessment concept is strongly supported in the literature — measuring agonist/antagonist ratios (conventional Hcon/Qcon hamstring-to-quadriceps, and functional Hecc/Qcon ratios) and side-to-side (bilateral) symmetry is a standard, validated use of isokinetic dynamometry, and these ratios are used in return-to-play and injury-risk screening. The specific mechanism (“two motors operate together … simultaneously”) is proprietary and unconfirmed externally. The preventive claim (“long before they surface as pain or injury”) is stronger than the evidence supports — conventional H/Q ratios are described in the literature as weak individual risk factors.
  • Evidence:
  • Recommendation: KEEP the balance-ratio-measurement concept; SOFTEN the preventive “long before they surface as pain or injury” to attributed/hedged language (e.g., “can help flag side-to-side asymmetries and muscle imbalances”). CONFIRM-CLIENT on the “simultaneous two-motor” mechanism.
  • Notes: Do not imply isokinetic ratios predict injury in a clinically decisive way — the literature calls them weak individual predictors.

4. Pressure-activated hydraulic maintains accuracy as oil temperature rises · 🟠 · ⚠️

  • In post: “The Grand Velocity Machine uses a pressure-activated hydraulic system designed to maintain accuracy even as oil temperature rises. In the catalogue’s own words, there is ‘no decrease in efficiency when oil temperature increases’.”
  • Finding: The underlying physics is TRUE and textbook — hydraulic oil viscosity decreases as temperature rises, which is exactly why a long clinic session changes resistance feel and why compensation matters. However, the specific claim that the proprietary Pressure Resistance System (PRS) maintains accuracy / “no decrease in efficiency” as oil warms is an internal/catalogue claim with no public independent verification.
  • Evidence:
  • Recommendation: KEEP the general principle (oil viscosity changes with temperature → compensation is the engineering rationale); SOFTEN the proprietary compensation to “designed to maintain accuracy” (the post already uses “designed to,” which is correct hedging). The quoted catalogue line “no decrease in efficiency when oil temperature increases” should be presented as the manufacturer’s claim, not as independent fact.
  • Notes: Cross-references the companion PRS Pressure Resistance System post, which should carry the deeper sourcing. The patent (Claim 9) does not cover this oil-temperature function — do not let the patent citation imply it does.

5. “Regenerate injured muscle tissue and improve performance” · 🔴 · 🔧

  • In post: “The machine is described in the catalogue as suitable for regenerating injured muscle tissue and improving performance — clinical outcomes that should be validated against your own caseload and, where possible, published evidence.”
  • Finding: HIGH-SENSITIVITY clinical claim. Isokinetic devices are established rehabilitation and assessment tools that support recovery of strength and function after injury. They do not biologically regenerate muscle tissue — “regeneration” in muscle biology refers to the repair/regrowth of muscle fibres (satellite-cell-mediated), which is not something a resistance device does. The “improve performance” half is supportable in general (isokinetic training can increase strength/power) but not as a guaranteed outcome for this specific machine. The post already hedges this well (“should be validated against your own caseload”), but the quoted catalogue verb “regenerate” should not appear as a stated capability.
  • Evidence:
  • Recommendation: SOFTEN (clinical review required). Suggested wording: “designed to support the rehabilitation and recovery of injured tissue, and to help rebuild strength and performance.” Remove the bare verb “regenerate” from any capability statement. Keep the post’s existing hedge (“clinical outcomes that should be validated against your own caseload”).
  • Notes: YMYL / ACCC-sensitive. Requires clinician sign-off before publish. This is the single highest clinical-risk word in the post.

6. “80 individual fields of data” via touchscreen + Smart System PC · 🟢 · ⚠️

  • In post: “The Grand Velocity Machine’s touchscreen control and Smart System PC display 80 individual fields of data — a deep dataset for tracking a client’s progress across weeks of rehabilitation or a full pre-season testing block.”
  • Finding: Catalogue spec. The figure matches the source deck exactly (“Displays 80 Individual Fields of Data”). No public independent source enumerates or verifies the field count; this is a manufacturer software spec and should be confirmed against the actual export/reporting interface.
  • Evidence:
    • Catalogue source (Machine 5 — Grand Velocity, Features): “Displays 80 Individual Fields of Data” — verbatim match.
    • No public source found enumerating the 80 fields or the export formats (CSV/PDF/etc.).
  • Recommendation: CONFIRM-CLIENT. Verify the exact field count and request the data-export format list (CSV / PDF / SQL / EMR integration) so the claim can be stated precisely. KEEP once confirmed.
  • Notes: 🟢 SPEC → CONFIRM-CLIENT per workflow. The “deep dataset” framing is fine.

7. POWER = FORCE × VELOCITY; measures watts · 🟢 · ✅

  • In post: “Because POWER = FORCE × VELOCITY, the system can measure and store watts of power generated, not just raw strength.”
  • Finding: Textbook physics. Mechanical power is the product of force and velocity, expressed in watts (SI). This is consistent with the companion Power = Force × Velocity post and the Dual Concentric Training sourcing.
  • Evidence:
    • Wikipedia — Power (physics) — “the mechanical power generated by a force F on a body moving at the velocity v can be expressed as the product: P = F · v”; SI unit = watt. (type: encyclopaedia / physics reference)
  • Recommendation: KEEP. Optionally CITE on the post.
  • Notes: No ACCC concern — statement of physical law.

8. “Formerly known as the IsoMed” / rename heritage · 🟢 · ⚠️

  • In post: “Formerly known as the IsoMed, it is a multi-functional, all-in-one unit …”
  • Finding: Confirmed in the internal catalogue content map: Machine 5 “Grand Velocity Machine” is mapped from old deck “IsoMed” (pg 16). This is a product-rename fact internal to the client; no public source confirms a former “IsoMed” product line, but that is expected for a pre-web/pre-rebrand product name.
  • Evidence:
    • Catalogue content source (machine map): “5 Grand Velocity Machine IsoMed pg 16 OLD PIC” and “Grand Velocity Machine <-- renamed from ‘IsoMed’.”
  • Recommendation: CONFIRM-CLIENT (trivial — confirm the prior product name spelling/capitalisation: “IsoMed”). KEEP.
  • Notes: No external sourcing needed for a self-referential rename.

9. “Patented” + Australian Patent No. 2020101146 covers the PRS / pressure-activated function · 🔴 · ⚠️

  • In post: “The catalogue describes the Grand Velocity Machine’s function as ‘patented’ and references Australian Patent No. 2020101146 for the Pressure Resistance System. Confirm the patent’s current scope and status — and whether it covers this machine’s pressure-activated function specifically — before publishing the word ‘patented’ as proven fact.” (The post carries a RESEARCH NEEDED blockquote here.)

  • Finding: The patent EXISTS and is REAL, but the blog’s RESEARCH NEEDED caution is fully warranted and the answer is partly no:

    Registry facts (IP Australia, current as of 18-Jun-2026):

    • Type: Innovation Patent (NOT a Standard Patent). Innovation Patents require only an “innovative step” (lower threshold than inventive step) and have a maximum 8-year term.
    • Status: Certified (certified 20-Aug-2020; certified patents are enforceable). Note the patent ceased 30-Jan-2025 for non-payment of renewal fees, then was revived via a Section 223 Extension of Time (allowed 26-Mar-2025); renewal paid 19-Jun-2025, paid-to date 25-June-2026, expiry 25-June-2028.
    • Title: “Multifunctional computerized isokinetic strength training and rehabilitation system.”
    • Inventor: MAYNARD, Alan William. Applicant (current): Kickoff, LLC (Puerto Rico, 00901) — assigned from Alan Maynard, request filed 18-Feb-2026, allowed 20-Feb-2026. (Client should confirm the relationship between Velocity Isokinetics and Kickoff, LLC — this affects who is entitled to mark the product “patented.”)
    • Filing/effective date: 25-June-2020. Grant: 15-July-2020.
    • Subject matter: The patent claims a multifunctional isokinetic exercise system — base, pedestal, height-adjustable vertical column, a rotary actuator (vane-type pump), a dual-concentric variable dual-chambered control valve with two rotatable dials (1–10 resistance scale, independent flexion/extension), angle + pressure sensors, A-to-D converter, and a display/reporting unit. It is a system-level patent on the machine architecture.
    • What it does NOT claim: the patent specification does not claim a “Pressure Resistance System,” a “pressure-activated hydraulic valve that maintains accuracy as oil temperature rises,” or any oil-temperature-compensation mechanism. The PRS / temperature-stability claims in the blog are therefore not covered by this patent.

    System context: Australia abolished new Innovation Patent filings after 25 August 2021; existing innovation patents run to their 8-year maximum. This patent expires 25-June-2028 regardless.

  • Evidence:

    • IP Australia — Application 2020101146 — “Patent application type: Innovation”; “Application status: Certified”; “Inventors: MAYNARD, Alan William”; “Applicant 1 name: Kickoff, LLC”; “Filing date: 25-June-2020”; “Paid to date: 25-June-2026”; “Expiry date: 25-June-2028”; Publication history shows “Patent Ceased 59/5 30-Jan-2025” then “Extensions of Time, Section 223 - Applications Allowed 59/26 26-June-2025”; Ownership changes: “New name: Kickoff, LLC / Previous name: MAYNARD, Alan.” (type: government patent register)
    • Google Patents — AU2020101146A4 — title “Multifunctional computerized isokinetic strength training and rehabilitation system”; abstract and claims describe the dual-concentric variable dual-chambered control valve, rotary actuator, sensors and display — no claim directed to oil-temperature compensation or a “Pressure Resistance System.” (type: patent full-text)
    • IP Australia — Innovation patents — confirms 25-Aug-2021 was the last filing day and the 8-year maximum term. (type: government)

  • Recommendation: ⚠️ CONFIRM-CLIENT + clarify before using “patented”:

    1. State the patent correctly as an Innovation Patent (not just “patent”) and ideally cite the number and “Innovation Patent” type, e.g., “Australian Innovation Patent 2020101146 (‘Multifunctional computerized isokinetic strength training and rehabilitation system’).”
    2. Do NOT cite 2020101146 as the patent for the “Pressure Resistance System” or for the oil-temperature-stability claim — the patent does not cover those. Either remove that linkage or confirm with the client whether a separate patent/application covers PRS (none was found in this search).
    3. Confirm entitlement: the applicant is now Kickoff, LLC (Puerto Rico). Confirm Kickoff is the correct owner of the Velocity Isokinetics mark/products and is entitled to mark the Grand Velocity Machine “patented” — this matters for ACCC “false or misleading” exposure if entitlement is unclear.
    4. Note the expiry: the patent expires 25-June-2028 (and Innovation Patents cannot be renewed beyond 8 years). Any “patented” marking should be reviewed at expiry.

  • Notes: This is the highest legal-risk item. The blog’s existing RESEARCH NEEDED blockquote is appropriate and should stay until items 1–3 above are resolved with the client. “Patent pending” or “patent applied for” must not be used — the patent is granted/certified.

10. Comparison to Biodex System — “positioned as an Australian-made alternative” · 🟠 · 🔧

  • In post: “established dynamometers such as the Biodex System. The Grand Velocity Machine is positioned as an Australian-designed, Australian-made alternative that brings something different: isokinetic, isometric and isotonic modes, dual-motor bilateral testing, and an emphasis on temperature-stable hydraulic accuracy — in a single multi-joint unit.” (The post carries a RESEARCH NEEDED blockquote here.)

  • Finding: The blog’s “positioned as an alternative” framing is appropriately soft and is the correct approach. To keep any implied comparison fair, note the published Biodex System 4 facts:

    Biodex System 4 (PRO) — official brochure facts:

    • Modes: six — Isokinetic, Isometric, Passive Motion, Isotonic, Reactive Eccentric, Eccentric. (The Grand Velocity claims three — isokinetic, isometric, isotonic.)
    • Speed: concentric up to 500°/sec, eccentric up to 300°/sec, passive as low as 0.25°/sec. (The Grand Velocity claims 2–600°/sec variable speed — a wider top end, but Biodex’s eccentric/passive ranges and very-low-speed capability are not matched by the catalogue spec.)
    • Torque: concentric up to 500 ft-lb (680 Nm); eccentric up to 400 ft-lb (542 Nm).
    • Evidence base: “Used in over 1,000 published studies”; explicit support for “bilateral comparisons, unilateral ratios” and ACL return-to-play criteria. Biodex is the de-facto reference standard in isokinetic research.
    • Footprint: the Grand Velocity patent itself cites Biodex System 4 Pro as requiring ~32 sq ft (~3 m²). The Grand Velocity’s own footprint is W 1.8 m × L 2.5 m ≈ 4.5 m² — i.e. larger than Biodex. Any implication that the Grand Velocity is more compact would be inaccurate.

    The post makes no explicit superiority claim (good). The risk is implied superiority via the phrase “brings something different.”

  • Evidence:

    • Biodex System 4 brochure (Physio-K mirror, FN 20-229 7/20) — “Featuring six modes of operation”; “Concentric speed up to 500 deg/sec”; “Eccentric speed up to 300 deg/sec”; “Passive speed as low as 0.25 deg/sec”; “Used in over 1,000 published studies”; “bilateral comparisons, unilateral ratios.” (type: competitor manufacturer brochure — primary source for Biodex specs)
    • Google Patents — AU2020101146A4 (Grand Velocity patent) — ¶0003: “newer models such as Biodex System 4 Pro System 4 Quick Set require 32 square feet area to be installed.” (type: patent — cites Biodex footprint)

  • Recommendation: KEEP the “positioned as an Australian-designed, Australian-made alternative” framing. Do not add any superiority claim (faster, more accurate, more modes, more compact) — the published Biodex specs do not support it on modes, evidence base, eccentric range, low-speed range, or footprint. Ensure “brings something different” is read as differentiation, not superiority. The post’s existing RESEARCH NEEDED blockquote is appropriate; it can be resolved now with the Biodex facts above.

  • Notes: ACCC misleading-conduct risk if any implied superiority is left to stand. Naming a competitor (“Biodex”) is acceptable in Australia provided the comparison is accurate and not misleading.

11. Product spec — speed range 2–600°/sec · 🟢 · ⚠️

  • In post: “Speed range: 2–600 deg/sec variable speed control.”
  • Finding: Catalogue spec; verbatim match to source deck (“Variable Speed Control (2 deg/sec - 600 deg/sec)”). The 600°/sec top end is at the higher end of isokinetic dynamometer ranges (Biodex System 4 tops out at 500°/sec concentric) — plausible but client-confirmable. No public independent source verifies the achievable speed of this specific machine.
  • Evidence:
    • Catalogue source (Machine 5 — Grand Velocity, Features): “Variable Speed Control (2 deg/sec - 600 deg/sec)” — verbatim match.
    • Biodex System 4 brochure — “Concentric speed up to 500 deg/sec” (context: comparable industry dynamometer ceiling). (type: competitor manufacturer brochure)
  • Recommendation: CONFIRM-CLIENT (the 2–600°/sec figure is a catalogue value; confirm against the final spec sheet). KEEP once confirmed.
  • Notes: 🟢 SPEC → CONFIRM-CLIENT.

12. Product spec — footprint W 1.8 m × L 2.5 m; bench −30° to 90°; rotary + linear motion · 🟢 · ⚠️

  • In post: “Footprint: W 1.8 m × L 2.5 m”; “Adjustable angle bench: −30° to 90°”; “Motion: rotary and linear”.
  • Finding: Catalogue specs; verbatim matches. Footprint “W: 1.8 metres L: 2.5 metres”; bench “Adjustable Angle Bench (-30 deg to 90 deg)”; features include “Rotary and Linear Motion.” All match the source deck exactly. (Note: the catalogue editorial-corrections log flagged a different machine — Ferocity Multi — with a “L: 20 metres” typo; the Grand Velocity’s 2.5 m length is internally consistent and not flagged.)
  • Evidence:
    • Catalogue source (Machine 5 — Grand Velocity): “W: 1.8 metres L: 2.5 metres”; “Adjustable Angle Bench (-30 deg to 90 deg)”; “Rotary and Linear Motion” — verbatim matches.
  • Recommendation: CONFIRM-CLIENT. KEEP once confirmed against the final spec sheet.
  • Notes: 🟢 SPEC → CONFIRM-CLIENT. The footprint is larger than Biodex System 4 Pro (~32 sq ft ≈ 3 m², per the Grand Velocity patent itself) — do not market compactness vs. Biodex.

13. Multi-joint coverage (hip, shoulder, elbow, back, ankle, wrist, knee) + unilateral-knee Range Limiter · 🟢 · ⚠️

  • In post: “It covers hip, shoulder, elbow, back, ankle and wrist, with a dedicated focus on unilateral knee function through an integrated Range Limiter device. The right motor rotates a full 180 degrees.”
  • Finding: Movements/regions list matches the catalogue (“CHEST PUSH/PULL; TRUNK/BACK FLEXION/EXTENSION; HIP ALL MOVEMENTS; ANKLE OPTIONAL; KNEE FLEXION/EXTENSION; SHOULDER ALL MOVEMENTS & PULL OVER; ELBOW FLEXION/EXTENSION; WRIST OPTIONAL”). “This multi-joint machine is for unilateral knee function with a Range Limiter device. The right motor rotates 180 degrees.” is verbatim from the catalogue overview. (Note: the post says “right motor rotates a full 180 degrees”; the catalogue says “rotates 180 degrees” — consistent.)
  • Evidence:
    • Catalogue source (Machine 5 — Grand Velocity): overview + movements list — verbatim matches.
  • Recommendation: CONFIRM-CLIENT. KEEP once confirmed.
  • Notes: 🟢 SPEC → CONFIRM-CLIENT. “Range Limiter” and “right motor rotates 180 degrees” are proprietary design details.

14. Test → Monitor → Rehabilitate workflow; “intelligent software for quick client setup” · 🟢 · 🟡

  • In post: “The Grand Velocity Machine is built around a three-stage rehabilitation workflow: 1. Test … 2. Monitor … 3. Rehabilitate … Intelligent software is designed for quick client setup.”
  • Finding: The test-assess-monitor-rehabilitate continuum is the standard model for isokinetic clinical use and is reflected in the Biodex brochure’s own “six phases of rehabilitation … proving need, progress, and outcome” framing. “Intelligent software for quick client setup” is a catalogue phrase (verbatim) describing the Smart System PC; not externally verifiable but a reasonable product description.
  • Evidence:
    • Biodex System 4 brochure — “Six phases of rehabilitation following the model of proving need, progress, and outcome.” (type: competitor manufacturer brochure — confirms the assessment→rehab continuum is industry-standard, not unique)
    • Catalogue source (Grand Velocity): “plus has intelligent software for quick client setup.” — verbatim.
  • Recommendation: KEEP. The workflow framing is standard and non-controversial. CONFIRM-CLIENT on the “intelligent software” specifics if any capability is asserted.
  • Notes: Do not present the workflow as unique to the Grand Velocity — it is the standard isokinetic-rehab model.

Open items for client / clinician / legal

  • PATENT (legal, must resolve before publish): Confirm (a) the product may be marked “patented” given the applicant is now Kickoff, LLC (Puerto Rico) — confirm Kickoff’s relationship to Velocity Isokinetics and entitlement; (b) whether a separate patent/application covers the “Pressure Resistance System” and oil-temperature stability — AU 2020101146 does not. Until resolved, describe 2020101146 accurately as an Innovation Patent covering a multifunctional computerized isokinetic system and do not link it to PRS/temperature claims. Note the patent expires 25-June-2028 and Innovation Patents cannot be renewed beyond 8 years.
  • CLINICAL (clinician sign-off required): Remove/replace “regenerate injured muscle tissue” — devices support rehabilitation, they do not biologically regenerate tissue. Suggested: “designed to support the rehabilitation and recovery of injured tissue.”
  • COMPARATIVE (legal): Keep the Biodex comparison at “positioned as an Australian-made alternative” — no superiority claim. Biodex offers six modes (vs three), is the published reference standard (>1,000 studies), and has a smaller footprint (~3 m² vs ~4.5 m²).
  • SPECS (client confirm): 2–600°/sec speed range; W 1.8 m × L 2.5 m footprint; −30° to 90° bench; 80 data fields (request the field list + export formats); two-motor unilateral/bilateral system; “Range Limiter”; “right motor rotates 180 degrees.” All match the catalogue verbatim and need final spec-sheet confirmation.
  • SOFTEN: (1) “regenerate injured muscle tissue” (Claim 5); (2) the preventive “long before they surface as pain or injury” balance-ratio wording (Claim 3); (3) any implied superiority in the Biodex comparison (Claim 10); (4) ensure the patent is described as an Innovation Patent and not linked to PRS (Claim 9).